Eyenovia announces planned retirement of lead independent director ken lee, jr.

New york, sept. 30, 2022 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), a pre-commercial ophthalmic technology company developing the optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced the planned retirement of lead independent director, ken lee, jr., effective today, september 30, 2022.
EYEN Ratings Summary
EYEN Quant Ranking